The invention relates to a diphenylaminopyrimidine and triazine compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, hydrate or solvate thereof:wherein A is C or N； X and Y are independently selected from hydrogen, halo, cyano, trifluoromethyl, alkoxy, alkyl, aryl, alkenyl, alkynyl and nitro； or X and Y, together with the atoms to which they are attached, form a phenyl or an heteroaromatic ring； R1 isR2 is CD3 or CD2CD3； R3 isR4 is hydrogen, methyl, trifluoromethyl, cyano or halo； R5 is hydrogen, alkyl, substituted and unsubstituted phenyl, allyl or propargyl； R6 and R7 are independently selected from hydrogen, alkyl, substituted and unsubstituted phenyl, allyl and propargyl； or R6 and R7, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocycloalkyl group. The compound herein has excellent pharmacodynamic and pharmacokinetic properties and ALK kinase inhibitory activity.
